We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Marina Biotech Awarded $733,000 in Grants for Qualifying Therapeutic Development Projects
News

Marina Biotech Awarded $733,000 in Grants for Qualifying Therapeutic Development Projects

Marina Biotech Awarded $733,000 in Grants for Qualifying Therapeutic Development Projects
News

Marina Biotech Awarded $733,000 in Grants for Qualifying Therapeutic Development Projects

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Marina Biotech Awarded $733,000 in Grants for Qualifying Therapeutic Development Projects"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Marina Biotech, Inc. has announced that it was awarded cash grants totaling approximately $733,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

"We are extremely pleased to receive the grants and to be recognized for our pre-clinical and clinical programs addressing unmet medical needs," said J. Michael French, President and CEO of Marina Biotech. "The QTDP grant program will help us fund these ongoing programs especially in this difficult economic environment."

The QTDP was created by Congress in March 2010 as part of the Patient Protection and Affordable Care Act and provides a tax credit or grant equal to 50% of eligible costs and expenses for tax years 2009 and 2010. The Department of Treasury further allocated these credits and grants among qualified applicants since the program was oversubscribed.

The Company submitted grant applications for three of its therapeutic development projects, namely CEQ508 for the treatment of Familial Adenomatous Polyposis, CEQ626 for the treatment of Inflammatory Bowel Disorder and the RNAi Therapeutics platform. It received grants for all three submitted projects.
Advertisement